Article Type
Changed
Thu, 03/28/2019 - 16:14
Display Headline
PRODUCT UPDATE

INTONE™ FOR URINARY INCONTINENCE: MUSCLE STIMULATION, FEEDBACK, TRACKING

InTone from InControl Medical, LLC, is a Class II FDA-cleared device that combines intravaginal muscle stimulation, exercises, biofeedback, and data reporting. A sensor in the device measures pressure to determine if the patient is doing the exercises properly while mild microcurrent stimulates the muscles. The biofeedback unit provides voice-guided instruction as the patient follows a daily 10-minute routine. Data records muscle isolation and strength on the hand-held controller; information can be downloaded into the clinician’s computer for review.

FOR MORE INFORMATION, VISIT www.incontrolmedical.com

IROUNDS™ OFFERS MOBILE/WEB PLATFORMS TO ENHANCE PHYSICIAN COMMUNICATION

iRounds.net was built to enable ObGyn physicians to communicate with each other, share call schedules, follow appointments, allow cross-coverage, and provide patient sign-out capabilities. Communication is secure, encrypted, and HIPAA-compliant. The physician’s office staff can interact to enter patient information, schedule procedures, update the call schedule, etc. Secure MD-to-MD calls can be made.

FOR MORE INFORMATION, VISIT www.irounds.net

USE GUIDEBOOK FROM AMA TO VERIFY INSURER-PROVIDED PROFILE REPORTS

Take Charge of Your Data is a new guidebook from the American Medical Association to help physicians understand and verify the accuracy of complex profile reports provided by health insurers based on collected claims data. Physicians need to confirm the accuracy of the practice data collected by insurers because these data drive public reporting, pay-for-performance, physician tiering, and narrow network programs. Using practical information and clear instructions, the guide simplifies the process of reviewing profile reports. The guide and supplementary standard report are available free to all physicians at the AMA’s Practice Management Center.

FOR MORE INFORMATION, VISIT http://bit.ly/OWERPLs

DIGICHART PROVIDES EHR AND PRACTICE MANAGEMENT TOOLS

digiChart OB-GYN, from digiChart, Inc, is a speciality-specific electronic health record (EHR) product developed to enhance ObGyn patient care and meet meaningful use requirements. PracticeSmart is an integrated EHR and practice management tool that allows the clinical, administrative, and financial parts of an ObGyn practice to “talk” to each other, mimicking typical office workflow. digiChart says its EHR program is preloaded with easy-to-edit ObGyn clinical treatment plans; there are no templates to build. The online patient portal and e-prescribing module are fully integrated and included in the pricing structure. All digiChart products run on an Internet-based platform to reduce cost and maintenance, increase security, and allow for automatic updates.

FOR MORE INFORMATION, VISIT www.digichart.com

MIFEPREX —TO END EARLY PREGNANCY

Mifeprex (mifepristone) from Danco Laboratories, is an FDA-approved nonsurgical option used alone or in combination with misoprostol to end an early pregnancy (within 49 days of the beginning of the patient’s last menstrual period). Taken orally by prescription only, this antiprogestational steroid blocks the activity of progesterone, which is required to maintain pregnancy. Mifeprex should not be used in cases of confirmed or suspected ectopic pregnancy (read Important Safety Information). Mifeprex is also used to treat tumors of the brain, endometriosis, and fibroids, or to induce labor.

FOR MORE INFORMATION, VISIT www.earlyoptionpill.com

Article PDF
Author and Disclosure Information

Issue
OBG Management - 24(09)
Publications
Topics
Page Number
56-56
Legacy Keywords
Product Update;Intone;urinary incontinence;muscle stimulation;InControl Medical;biofeedback;iRounds;AMA;American Medical Association;health insurers;practice claims data;Digichart;electronic health records;EHR;mifepristone;Mifeprex;Danco Laboratories;misoprostol;end early pregnancy;antiprogestational steroid;progesterone;ectopic pregnancy;practice management;physician-to-physician communication;cross-coverage;HIPAA compliant;FDA;
Sections
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

INTONE™ FOR URINARY INCONTINENCE: MUSCLE STIMULATION, FEEDBACK, TRACKING

InTone from InControl Medical, LLC, is a Class II FDA-cleared device that combines intravaginal muscle stimulation, exercises, biofeedback, and data reporting. A sensor in the device measures pressure to determine if the patient is doing the exercises properly while mild microcurrent stimulates the muscles. The biofeedback unit provides voice-guided instruction as the patient follows a daily 10-minute routine. Data records muscle isolation and strength on the hand-held controller; information can be downloaded into the clinician’s computer for review.

FOR MORE INFORMATION, VISIT www.incontrolmedical.com

IROUNDS™ OFFERS MOBILE/WEB PLATFORMS TO ENHANCE PHYSICIAN COMMUNICATION

iRounds.net was built to enable ObGyn physicians to communicate with each other, share call schedules, follow appointments, allow cross-coverage, and provide patient sign-out capabilities. Communication is secure, encrypted, and HIPAA-compliant. The physician’s office staff can interact to enter patient information, schedule procedures, update the call schedule, etc. Secure MD-to-MD calls can be made.

FOR MORE INFORMATION, VISIT www.irounds.net

USE GUIDEBOOK FROM AMA TO VERIFY INSURER-PROVIDED PROFILE REPORTS

Take Charge of Your Data is a new guidebook from the American Medical Association to help physicians understand and verify the accuracy of complex profile reports provided by health insurers based on collected claims data. Physicians need to confirm the accuracy of the practice data collected by insurers because these data drive public reporting, pay-for-performance, physician tiering, and narrow network programs. Using practical information and clear instructions, the guide simplifies the process of reviewing profile reports. The guide and supplementary standard report are available free to all physicians at the AMA’s Practice Management Center.

FOR MORE INFORMATION, VISIT http://bit.ly/OWERPLs

DIGICHART PROVIDES EHR AND PRACTICE MANAGEMENT TOOLS

digiChart OB-GYN, from digiChart, Inc, is a speciality-specific electronic health record (EHR) product developed to enhance ObGyn patient care and meet meaningful use requirements. PracticeSmart is an integrated EHR and practice management tool that allows the clinical, administrative, and financial parts of an ObGyn practice to “talk” to each other, mimicking typical office workflow. digiChart says its EHR program is preloaded with easy-to-edit ObGyn clinical treatment plans; there are no templates to build. The online patient portal and e-prescribing module are fully integrated and included in the pricing structure. All digiChart products run on an Internet-based platform to reduce cost and maintenance, increase security, and allow for automatic updates.

FOR MORE INFORMATION, VISIT www.digichart.com

MIFEPREX —TO END EARLY PREGNANCY

Mifeprex (mifepristone) from Danco Laboratories, is an FDA-approved nonsurgical option used alone or in combination with misoprostol to end an early pregnancy (within 49 days of the beginning of the patient’s last menstrual period). Taken orally by prescription only, this antiprogestational steroid blocks the activity of progesterone, which is required to maintain pregnancy. Mifeprex should not be used in cases of confirmed or suspected ectopic pregnancy (read Important Safety Information). Mifeprex is also used to treat tumors of the brain, endometriosis, and fibroids, or to induce labor.

FOR MORE INFORMATION, VISIT www.earlyoptionpill.com

INTONE™ FOR URINARY INCONTINENCE: MUSCLE STIMULATION, FEEDBACK, TRACKING

InTone from InControl Medical, LLC, is a Class II FDA-cleared device that combines intravaginal muscle stimulation, exercises, biofeedback, and data reporting. A sensor in the device measures pressure to determine if the patient is doing the exercises properly while mild microcurrent stimulates the muscles. The biofeedback unit provides voice-guided instruction as the patient follows a daily 10-minute routine. Data records muscle isolation and strength on the hand-held controller; information can be downloaded into the clinician’s computer for review.

FOR MORE INFORMATION, VISIT www.incontrolmedical.com

IROUNDS™ OFFERS MOBILE/WEB PLATFORMS TO ENHANCE PHYSICIAN COMMUNICATION

iRounds.net was built to enable ObGyn physicians to communicate with each other, share call schedules, follow appointments, allow cross-coverage, and provide patient sign-out capabilities. Communication is secure, encrypted, and HIPAA-compliant. The physician’s office staff can interact to enter patient information, schedule procedures, update the call schedule, etc. Secure MD-to-MD calls can be made.

FOR MORE INFORMATION, VISIT www.irounds.net

USE GUIDEBOOK FROM AMA TO VERIFY INSURER-PROVIDED PROFILE REPORTS

Take Charge of Your Data is a new guidebook from the American Medical Association to help physicians understand and verify the accuracy of complex profile reports provided by health insurers based on collected claims data. Physicians need to confirm the accuracy of the practice data collected by insurers because these data drive public reporting, pay-for-performance, physician tiering, and narrow network programs. Using practical information and clear instructions, the guide simplifies the process of reviewing profile reports. The guide and supplementary standard report are available free to all physicians at the AMA’s Practice Management Center.

FOR MORE INFORMATION, VISIT http://bit.ly/OWERPLs

DIGICHART PROVIDES EHR AND PRACTICE MANAGEMENT TOOLS

digiChart OB-GYN, from digiChart, Inc, is a speciality-specific electronic health record (EHR) product developed to enhance ObGyn patient care and meet meaningful use requirements. PracticeSmart is an integrated EHR and practice management tool that allows the clinical, administrative, and financial parts of an ObGyn practice to “talk” to each other, mimicking typical office workflow. digiChart says its EHR program is preloaded with easy-to-edit ObGyn clinical treatment plans; there are no templates to build. The online patient portal and e-prescribing module are fully integrated and included in the pricing structure. All digiChart products run on an Internet-based platform to reduce cost and maintenance, increase security, and allow for automatic updates.

FOR MORE INFORMATION, VISIT www.digichart.com

MIFEPREX —TO END EARLY PREGNANCY

Mifeprex (mifepristone) from Danco Laboratories, is an FDA-approved nonsurgical option used alone or in combination with misoprostol to end an early pregnancy (within 49 days of the beginning of the patient’s last menstrual period). Taken orally by prescription only, this antiprogestational steroid blocks the activity of progesterone, which is required to maintain pregnancy. Mifeprex should not be used in cases of confirmed or suspected ectopic pregnancy (read Important Safety Information). Mifeprex is also used to treat tumors of the brain, endometriosis, and fibroids, or to induce labor.

FOR MORE INFORMATION, VISIT www.earlyoptionpill.com

Issue
OBG Management - 24(09)
Issue
OBG Management - 24(09)
Page Number
56-56
Page Number
56-56
Publications
Publications
Topics
Article Type
Display Headline
PRODUCT UPDATE
Display Headline
PRODUCT UPDATE
Legacy Keywords
Product Update;Intone;urinary incontinence;muscle stimulation;InControl Medical;biofeedback;iRounds;AMA;American Medical Association;health insurers;practice claims data;Digichart;electronic health records;EHR;mifepristone;Mifeprex;Danco Laboratories;misoprostol;end early pregnancy;antiprogestational steroid;progesterone;ectopic pregnancy;practice management;physician-to-physician communication;cross-coverage;HIPAA compliant;FDA;
Legacy Keywords
Product Update;Intone;urinary incontinence;muscle stimulation;InControl Medical;biofeedback;iRounds;AMA;American Medical Association;health insurers;practice claims data;Digichart;electronic health records;EHR;mifepristone;Mifeprex;Danco Laboratories;misoprostol;end early pregnancy;antiprogestational steroid;progesterone;ectopic pregnancy;practice management;physician-to-physician communication;cross-coverage;HIPAA compliant;FDA;
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media